Page last updated: 2024-08-21

arsenic trioxide and Myelodysplastic Syndromes

arsenic trioxide has been researched along with Myelodysplastic Syndromes in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (66.67)	29.6817
2010's	15 (29.41)	24.3611
2020's	2 (3.92)	2.80

Authors

Authors	Studies
Huang, X; Liu, R; Liu, Y; Yang, H; Zou, X	1
Ai, H; Chen, L; Mi, RH; Song, YP; Wang, Q; Wei, XD; Yin, QS	1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA	1
Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J	1
Fu, R; Huang, L; Jiang, H; Li, L; Liu, Z	1
Mehta, SV; Shukla, SN; Vora, HH	1
Guan, X; Liu, J; Lu, R; Ma, J; Shao, X; Shao, Z; Zhan, Z; Zhao, J	1
Jin, J; Qian, W; Tong, H; Wang, Y; Xu, W	1
Fan, J; Guo, K; Li, Y; Li, Z; Weng, G; Wu, J; Xia, P; Zeng, Y; Zheng, R	1
Cen, JN; Gao, HQ; Hua, HY; Sun, AN; Wu, LL	1
Schiffer, CA; Srinivasan, S	1
Cen, J; Chen, Z; Gu, M; Liu, D; Qi, X	1
Ma, R; Xu, S	1
Gotlib, J; Greenberg, PL	1
Sekeres, MA	3
Gotlib, J; Oh, ST	1
Allen-Bard, S; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Segovia, J	1
Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R	1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE	1
Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P	1
Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D	1
Guo, L; Hou, J; Shi, H; Wei, W; Zhang, Y; Zhou, F	1
Cilloni, D; Galimberti, S; Gioia, D; Guerrini, F; Levis, A; Messa, E; Palumbo, GA; Petrini, I; Petrini, M; Salvi, F	1
Lin, M; Tong, H	1
Beran, M; DiPersio, J; Greenberg, P; List, A; Rosenfeld, CS; Slack, J; Vey, N	1
Chen, JL; Li, Q; Li, RS; Song, XZ; Xu, M	1
Cai, Z; Lin, MF; Tong, HY; Xiong, H	1
Vey, N	1
Alvi, MI; Buonamici, S; Candoni, A; Chaudary, NI; Galili, N; Gallegos, JA; Gezer, S; Imran, M; Li, D; Lisak, L; Mumtaz, M; Nucifora, G; Pervaiz, H; Raza, A; Reddy, P; Singer, J; Tahir, S; Venugopal, P	1
Baldus, C; Hofmann, WK; Thiel, E; Uharek, L	1
Deeg, HJ; Li, X; Pu, Q; Shen, WM; Tohyama, K	1
Fukumoto, JS; Greenberg, PL	1
Balk, RA; Hassaballa, HA; Lateef, OB; Silver, MR	1
Abbasi, N; Deeg, HJ; Kerbauy, DM; Lesnikov, V; Scott, B; Seal, S	1
Jin, J; Lin, MF; Qian, WB; Tong, HY; Xu, WL	1
Jin, J; Lu, J; Xu, WL	1
Stone, RM	1
Bosly, A; Bowen, D; Burnett, A; Casadevall, N; Dennis, M; Dombret, H; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Legros, L; Ribrag, V; Vey, N	1
Douer, D; Hainsworth, JD; List, AF; Mason, J; Rizzieri, D; Saleh, M; Schiller, GJ; Slack, J	1
Jin, J; Liu, J; Ni, W; Qian, W; Xu, W	1
Avivi, I; Gesundheit, B; Ofran, Y; Or, R; Rowe, JM; Zuckerman, T	1
Jin, J; Lu, J	1
Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS	1
Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL	1
Chiodino, C; Donelli, A; Panissidi, T; Roncaglia, R; Torelli, G	1
Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S	1
Miller, WH	1
List, AF	1

Reviews

15 review(s) available for arsenic trioxide and Myelodysplastic Syndromes

Article	Year
The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Network Meta-Analysis; Oxides; Treatment Outcome	2023
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 04-15, Volume: 127, Issue:8 Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine	2021
Current treatment options and strategies for myelodysplastic syndromes. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10 Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Blood Transfusion; Clinical Trials as Topic; Comorbidity; Disease Progression; Erythropoietin; Farnesyltranstransferase; Hematinics; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Oxides; Recombinant Proteins; Social Class; Stem Cell Transplantation	2008
[Progress of arsenic trioxide in treating myelodysplastic syndromes]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2009, Volume: 29, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Oxides	2009
Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4 Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide	2003
Arsenic trioxide as a treatment for myelodysplastic syndrome. Current hematologic malignancy reports, 2006, Volume: 1, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors	2006
Antiangiogenesis in myelodysplastic syndrome. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide	2011
Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia, 2003, Volume: 17, Issue:8 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Physiological Phenomena; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome	2003
Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase II as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome	2004
Arsenic trioxide as a treatment for myelodysplastic syndrome. Current hematology reports, 2005, Volume: 4, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors	2005
Management of patients with higher risk myelodysplastic syndromes. Critical reviews in oncology/hematology, 2005, Volume: 56, Issue:2 Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome	2005
New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Oxides	2007
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin	2002
Molecular targets of arsenic trioxide in malignant cells. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides	2002
New approaches to the treatment of myelodysplasia. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome	2002

Trials

9 trial(s) available for arsenic trioxide and Myelodysplastic Syndromes

Article	Year
[Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3 Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; DNA Methylation; Female; Humans; Inhibitor of Differentiation Proteins; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Treatment Outcome; Young Adult	2014
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leukemia research, 2011, Volume: 35, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Oxides; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome	2011
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer, 2011, Mar-15, Volume: 117, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome	2011
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer investigation, 2011, Volume: 29, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib	2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. American journal of hematology, 2011, Volume: 86, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult	2011
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leukemia research, 2012, Volume: 36, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Oxides; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome	2012
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome	2006
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome	2006
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin	2008

Other Studies

27 other study(ies) available for arsenic trioxide and Myelodysplastic Syndromes

Article	Year
[The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome]. Zhonghua nei ke za zhi, 2019, Dec-01, Volume: 58, Issue:12 Topics: Arsenic Trioxide; Decitabine; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome	2019
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. Journal of controlled release : official journal of the Controlled Release Society, 2017, Dec-28, Volume: 268 Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution	2017
Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2019, Volume: 67, Issue:7 Topics: Acetylcysteine; Antioxidants; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Myelodysplastic Syndromes; Reactive Oxygen Species	2019
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma, 2013, Volume: 60, Issue:6 Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult	2013
Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome. PloS one, 2014, Volume: 9, Issue:11 Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Down-Regulation; Female; Humans; Myelodysplastic Syndromes; NF-kappa B; Oxides; Poly(ADP-ribose) Polymerases; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Telomerase; Transcription Factor AP-1; X-Linked Inhibitor of Apoptosis Protein	2014
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncology reports, 2016, Volume: 36, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Myelodysplastic Syndromes; Oxides; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Stem Cells; Survivin	2016
Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line. Molecular medicine reports, 2016, Volume: 14, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Humans; Myelodysplastic Syndromes; Oxides; Phenanthrenes; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species	2016
Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells. International journal of molecular medicine, 2008, Volume: 22, Issue:1 Topics: Adult; Aged; Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Cell Cycle; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Leukocytes, Mononuclear; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Oxides; Tetradecanoylphorbol Acetate; Up-Regulation	2008
Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Current hematologic malignancy reports, 2008, Volume: 3, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide	2008
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of hematology & oncology, 2012, Sep-10, Volume: 5 Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Gene Expression; Genes, bcl-2; Humans; Male; Myelodysplastic Syndromes; Oxides; Real-Time Polymerase Chain Reaction	2012
[Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2002, Volume: 23, Issue:12 Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2002
[Analysis of caspases activity of hematopoietic progenitor cells and its significance in myelodysplastic syndromes]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:11 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Caspases; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Oxides	2003
[Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2004, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Division; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger	2004
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leukemia research, 2004, Volume: 28, Issue:8 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Lineage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Spleen; Thalidomide; Transcription Factors; Zinc Fingers	2004
Nursing considerations for nontraditional treatment approaches to hematologic malignancies. ONS news, 2004, Volume: 19, Issue:9 Suppl Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome	2004
Therapeutic spectrum in the treatment of myelodysplastic syndromes. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes; Oxides; Transplantation, Autologous; Transplantation, Homologous	2004
[Biologic changes in MDS-L cell line induced by As2O3 and/or TRAIL]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2004, Volume: 25, Issue:10 Topics: Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Cyclin-Dependent Kinase Inhibitor p15; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Immunohistochemistry; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; TNF-Related Apoptosis-Inducing Ligand	2004
Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome. Journal of critical care, 2005, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Male; Myelodysplastic Syndromes; Oxides; Respiratory Distress Syndrome	2005
NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood, 2005, Dec-01, Volume: 106, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Enzyme Activation; Etanercept; Flow Cytometry; Glutathione; Growth Inhibitors; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Myelodysplastic Syndromes; NF-kappa B; Oxides; Protein Transport; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2005
[Study on the mechanisms of telomerase regulations during apoptosis of the human MDS-RAEB cell line MUTZ-1 cells induced by arsenic trioxide]. Zhongguo shi yan xue ye xue za zhi, 2005, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Telomeric Repeat Binding Protein 2	2005
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2006, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Oxides; Random Allocation; Survival Rate; Thalidomide; Tumor Cells, Cultured	2006
Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Humans; Infusions, Intravenous; Myelodysplastic Syndromes; Oxides; Treatment Outcome	2006
Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leukemia research, 2007, Volume: 31, Issue:3 Topics: Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Beclin-1; Cell Death; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, T-Cell; Membrane Proteins; Myelodysplastic Syndromes; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Up-Regulation	2007
Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome. American journal of hematology, 2007, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Pulmonary Alveoli; Respiratory Distress Syndrome; Syndrome	2007
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2006, Volume: 44, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Humans; I-kappa B Proteins; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Mitochondria; Myelodysplastic Syndromes; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide	2006
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2007, Volume: 38, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides	2007
Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica, 2000, Volume: 85, Issue:9 Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Culture Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Oxides	2000